David Funt, MD
Plastic and Reconstructive Surgery · Woodmere, NYNPI 1295802940
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $202,065 of the $295,494 with a category attached, or 68.4%. 5 manufacturers reported payments, led by Merz North America, Inc. at 59.3% of the total. Reporting peaked in 2019 at $105,336 and has fallen 68.9% since, to $32,766 in 2025. Among plastic and reconstructive surgery clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 232 payments — averaging $1273.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merz North America, Inc.$175K
- AbbVie$67K
- Galderma Laboratories, L.p.$53K
- KCI USA, Inc.$41
- Kowa Pharmaceuticals America, Inc.$20
Across 31 payments — averaging $3142.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Cleerly, Inc.$77K
- Zealand Pharma A/s$20K
What the payments were for
- Consulting fees$202,06568%
- Speaking & faculty fees$47,66316%
- Travel & lodging$37,14913%
- Food & beverage$8,5473%
- Education$690%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merz North America, Inc. | 150 | $175,145 |
| AbbVie(2 entities) | 59 | $66,955 |
| Galderma Laboratories, L.p. | 21 | $53,332 |
| KCI USA, Inc. | 1 | $41 |
| Kowa Pharmaceuticals America, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XEOMIN$63,447
- BOTOX COSMETIC$30,118
- BOTOX$905
How this compares
$295,494 in reported general payments places this provider in the 95th percentile of 219 plastic and reconstructive surgery providers in New York.
See all plastic and reconstructive surgery providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ValacyclovirValacyclovir Hcl | 16 | $183 |
| Cefadroxil | 30 | $153 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 25 | $113 |
| Ondansetron OdtOndansetron | 21 | $41 |
Paid to pharmacies, not to this prescriber.
Other plastic and reconstructive surgery in Woodmere
- Thomas DavenportGarden City$2.8M
- Howard LangsteinRochester$350K
- James BradleyNew Hyde Park$306K
- Robert GrantNew York$207K
- Christine RohdeNew York$180K
- Steven LevineNew York$108K
- Tara HustonStony Brook$95K
- Theodore DiktabanNew York$83K
- Jeffrey RidhaSaratoga Springs$50K
- Evan GarfeinBronx$45K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.